Parkinson's Disease (PD) Drugs Market Report – Research, Industry Analysis Reports and Market Demands

Global Parkinson's Disease (PD) Drugs Market Insights, Forecast to 2025

Request for Sample of this report

Buy now

Table of Content

1 Study Coverage

1.1 Parkinson's Disease (PD) Drugs Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
- 1.4.1 Global Parkinson's Disease (PD) Drugs Market Size Growth Rate by Product
- 1.4.2 Dopamine Agonist
- 1.4.3 Monoamine Oxidase Inhibitors
- 1.4.4 Acetylcholinesterase Inhibitors
- 1.4.5 Glutamate Inhibitors
1.5 Market by End User
- 1.5.1 Global Parkinson's Disease (PD) Drugs Market Size Growth Rate by End User
- 1.5.2 Hospital
- 1.5.3 Family
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary

2.1 Global Parkinson's Disease (PD) Drugs Market Size
- 2.1.1 Global Parkinson's Disease (PD) Drugs Revenue 2014-2025
- 2.1.2 Global Parkinson's Disease (PD) Drugs Sales 2014-2025
2.2 Parkinson's Disease (PD) Drugs Growth Rate by Regions
- 2.2.1 Global Parkinson's Disease (PD) Drugs Sales by Regions
- 2.2.2 Global Parkinson's Disease (PD) Drugs Revenue by Regions

3 Breakdown Data by Manufacturers

3.1 Parkinson's Disease (PD) Drugs Sales by Manufacturers
- 3.1.1 Parkinson's Disease (PD) Drugs Sales by Manufacturers
- 3.1.2 Parkinson's Disease (PD) Drugs Sales Market Share by Manufacturers
- 3.1.3 Global Parkinson's Disease (PD) Drugs Market Concentration Ratio (CR5 and HHI)
3.2 Parkinson's Disease (PD) Drugs Revenue by Manufacturers
- 3.2.1 Parkinson's Disease (PD) Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Parkinson's Disease (PD) Drugs Revenue Share by Manufacturers (2014-2019)
3.3 Parkinson's Disease (PD) Drugs Price by Manufacturers
3.4 Parkinson's Disease (PD) Drugs Manufacturing Base Distribution, Product Types
- 3.4.1 Parkinson's Disease (PD) Drugs Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Parkinson's Disease (PD) Drugs Product Type
- 3.4.3 Date of International Manufacturers Enter into Parkinson's Disease (PD) Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

4.1 Global Parkinson's Disease (PD) Drugs Sales by Product
4.2 Global Parkinson's Disease (PD) Drugs Revenue by Product
4.3 Parkinson's Disease (PD) Drugs Price by Product

5 Breakdown Data by End User

5.1 Overview
5.2 Global Parkinson's Disease (PD) Drugs Breakdown Data by End User

6 North America

6.1 North America Parkinson's Disease (PD) Drugs by Countries
- 6.1.1 North America Parkinson's Disease (PD) Drugs Sales by Countries
- 6.1.2 North America Parkinson's Disease (PD) Drugs Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
6.2 North America Parkinson's Disease (PD) Drugs by Product
6.3 North America Parkinson's Disease (PD) Drugs by End User

7 Europe

7.1 Europe Parkinson's Disease (PD) Drugs by Countries
- 7.1.1 Europe Parkinson's Disease (PD) Drugs Sales by Countries
- 7.1.2 Europe Parkinson's Disease (PD) Drugs Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
7.2 Europe Parkinson's Disease (PD) Drugs by Product
7.3 Europe Parkinson's Disease (PD) Drugs by End User

8 Asia Pacific

8.1 Asia Pacific Parkinson's Disease (PD) Drugs by Countries
- 8.1.1 Asia Pacific Parkinson's Disease (PD) Drugs Sales by Countries
- 8.1.2 Asia Pacific Parkinson's Disease (PD) Drugs Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
8.2 Asia Pacific Parkinson's Disease (PD) Drugs by Product
8.3 Asia Pacific Parkinson's Disease (PD) Drugs by End User

9 Central & South America

9.1 Central & South America Parkinson's Disease (PD) Drugs by Countries
- 9.1.1 Central & South America Parkinson's Disease (PD) Drugs Sales by Countries
- 9.1.2 Central & South America Parkinson's Disease (PD) Drugs Revenue by Countries
- 9.1.3 Brazil
9.2 Central & South America Parkinson's Disease (PD) Drugs by Product
9.3 Central & South America Parkinson's Disease (PD) Drugs by End User

10 Middle East and Africa

10.1 Middle East and Africa Parkinson's Disease (PD) Drugs by Countries
- 10.1.1 Middle East and Africa Parkinson's Disease (PD) Drugs Sales by Countries
- 10.1.2 Middle East and Africa Parkinson's Disease (PD) Drugs Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
10.2 Middle East and Africa Parkinson's Disease (PD) Drugs by Product
10.3 Middle East and Africa Parkinson's Disease (PD) Drugs by End User

11 Company Profiles

12 Future Forecast

12.1 Parkinson's Disease (PD) Drugs Market Forecast by Regions
- 12.1.1 Global Parkinson's Disease (PD) Drugs Sales Forecast by Regions 2019-2025
- 12.1.2 Global Parkinson's Disease (PD) Drugs Revenue Forecast by Regions 2019-2025
12.2 Parkinson's Disease (PD) Drugs Market Forecast by Product
- 12.2.1 Global Parkinson's Disease (PD) Drugs Sales Forecast by Product 2019-2025
- 12.2.2 Global Parkinson's Disease (PD) Drugs Revenue Forecast by Product 2019-2025
12.3 Parkinson's Disease (PD) Drugs Market Forecast by End User
12.4 North America Parkinson's Disease (PD) Drugs Forecast
12.5 Europe Parkinson's Disease (PD) Drugs Forecast
12.6 Asia Pacific Parkinson's Disease (PD) Drugs Forecast
12.7 Central & South America Parkinson's Disease (PD) Drugs Forecast
12.8 Middle East and Africa Parkinson's Disease (PD) Drugs Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

14.1 Value Chain Analysis
14.2 Parkinson's Disease (PD) Drugs Customers
14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
16.2 Author Details

Description

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by damage to the dopaminergic neurons located in various parts of the brain, including the substantia nigra.
The emergence of gene therapy to reverse the progression of PD is one of the key trends that will gain traction in the market for parkinsons drugs throughout the estimated period.
The global Parkinson's Disease (PD) Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Parkinson's Disease (PD) Drugs market based on company, product type, end user and key regions.

This report studies the global market size of Parkinson's Disease (PD) Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Parkinson's Disease (PD) Drugs in these regions.
This research report categorizes the global Parkinson's Disease (PD) Drugs market by top players/brands, region, type and end user. This report also studies the global Parkinson's Disease (PD) Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Boehringer Ingelheim
GlaxoSmithKline
Novartis
Teva Pharmaceutical Industries
AbbVie
Abital Pharma
Addex Therapeutics
Biogen
Eisai
Eli Lilly
F. Hoffmann-La Roche
H. Lundbeck
Impax Laboratories
Kyowa Hakko Kirin
Otsuka Pharmaceutical
Pfizer

Market size by Product
Dopamine Agonist
Monoamine Oxidase Inhibitors
Acetylcholinesterase Inhibitors
Glutamate Inhibitors
Market size by End User
Hospital
Family

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Parkinson's Disease (PD) Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Parkinson's Disease (PD) Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Parkinson's Disease (PD) Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Parkinson's Disease (PD) Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Parkinson's Disease (PD) Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Parkinson's Disease (PD) Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.